Browsing Tag
Eftilagimod Alfa
7 posts
Immutep shares surge 27% as efti strategy narrows after TACTI-004 failure
Immutep Limited is narrowing eftilagimod alfa development to two oncology settings and returning to 200-litre manufacturing after finding structural differences between the material used in failed Phase III TACTI-004 and earlier successful studies.
Immutep (NASDAQ: IMMP) jumps 15% as efti review points to manufacturing differences
Immutep has identified potentially relevant structural differences between 200-litre and 2,000-litre efti manufacturing batches after the TACTI-004 failure, prompting a return to 200-litre production and a narrower clinical strategy.
Why eftilagimod alfa’s soft tissue sarcoma data now matters more than ever for Immutep Limited
Immutep Limited’s soft tissue sarcoma data may now define eftilagimod alfa’s future. Find out why this could reshape its oncology strategy.
Immutep (ASX: IMM) surges 48% on FDA orphan drug designation: Is the STS pivot the new thesis?
Immutep (ASX: IMM) jumped 48% after the FDA granted orphan drug status for eftilagimod alfa in soft tissue sarcoma. Here is what the EFTISARC-NEO data means for the investment case.
Why Immutep Limited halted its lung cancer trial and how the decision reshapes its immunotherapy strategy (NASDAQ: IMMP)
Immutep Limited halts the TACTI-004 Phase III lung cancer trial. Discover what the futility result means for eftilagimod alfa and LAG-3 immunotherapy.
Immutep (ASX: IMM) closing in on critical readout — biotech traders discuss risk vs reward heading into 2026
Immutep Limited surpasses 170 patients in its global Phase III NSCLC trial, setting up a 2026 futility readout that could redefine its immunotherapy pipeline.
Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of…